secwatch.observer — SEC 8-K summary
======================================

Issuer:     INSMED Inc (INSM)
CIK:        0001104506
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001140361-25-005570
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA will not hold AdComm for Insmed's brensocatib; PDUFA date Aug 12, 2025
--------------------------------------------------------------------------

- FDA communicated in Day 74 letter no advisory committee meeting is currently planned.
- Priority review reaffirmed with PDUFA target action date of August 12, 2025.
- NDA for non-CF bronchiectasis is based on data from the Phase 3 ASPEN study.
- Brensocatib could be the first approved treatment for bronchiectasis and first DPP1 inhibitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/0001140361-25-005570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1104506/000114036125005570/ef20044166_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-005570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer